glp 1 type 2 diabetes GLP-1 receptor agonists are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read List of approved and pending

They have not been reviewed, evaluated, or approved by regulatory authorities for the diagnosis, treatment, cure, or prevention of any disease or medical condition

Many GLP-1s are FDA approved for more than just weight loss, including type 2 diabetes, cardiovascular risk reduction, and even stroke prevention in certain populations, says Supriya Rao, MD, an obesity physician and the director of medical weight loss at Lowell General Hospital in Lowell, Massachusetts

A minimum of 12 hours is recommended to allow alcohols suppressive effects on the hypothalamic-pituitary axis to resolve

(2021) 70:S99

Pancreatitis Concerns Early concerns about pancreatitis risk with GLP-1 medications have been largely dispelled by recent research